Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015

Sarah Knerr, Erin J A Bowles, Kathleen A Leppig, Diana S M Buist, Hongyuan Gao, Karen J Wernli, Sarah Knerr, Erin J A Bowles, Kathleen A Leppig, Diana S M Buist, Hongyuan Gao, Karen J Wernli

Abstract

Background: Genetic testing to determine BRCA status has been available for over two decades, but there are few population-based studies of test diffusion. We report 10-year trends in BRCAtesting in an integrated health-care system with long-standing access to genetic services.

Methods: A cohort of women aged 18 years and older was created to ascertain BRCA testing (n = 295 087). Annual testing rates between 2005 and 2015 were calculated in all women with and without incident (ie, newly diagnosed) breast and ovarian cancers and in clinically eligible subgroups by family cancer history, personal cancer history, and age at diagnosis. Secular trends were assessed using Poisson regression. Women tested early (2005-2008), midway (2009-2012), and late (2013-2015) in the study period were compared in cross-sectional analyses.

Results: Between 2005 and 2015, annual testing rates increased from 0.6/1000 person-years (pys) (95% confidence interval [CI] = 0.4 to 0.7/1000 pys) to 0.8/1000 pys (95% CI = 0.6 to 1.0/1000 pys) in women without incident breast or ovarian cancers. Rates decreased from 71.5/1000 pys (95% CI = 42.4 to 120.8/1000 pys) to 44.4/1000 pys (95% CI = 35.5 to 55.6/1000 pys) in women with incident diagnoses, despite improvements in provision of timely BRCA testing during this time frame. We found no evidence of secular trends in clinically eligible subgroups including women with family history indicating increased hereditary cancer risk, but no personal cancer history. At the end of the study period, 97.0% (95% CI = 96.6% to 97.3%) of these women remained untested.

Conclusion: Many eligible women did not receive BRCA testing despite having insurance coverage and access to specialty genetic services, underscoring challenges to primary and secondary hereditary cancer prevention.

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Personal and family cancer history and contributed person-time for three hypothetical women. BC = breast cancer; BCSC = Breast Cancer Surveillance Consortium; D = death; DX = diagnosis; E = study entry; OC = ovarian cancer; T = BRCA test; SEER = Surveillance, Epidemiology, and End Results Registry.
Figure 2.
Figure 2.
Annual BRCAtesting rates in women with and without incident breast and ovarian cancer diagnoses, 2005–2015. Error bars indicate 95% confidence intervals for annual rates. BC = breast cancer; OC = ovarian cancer.

References

    1. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet. 2008;91:321–345.
    1. Norquist BM, Harrell MI, Brady MF et al. . Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;24:482–490.
    1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;2511:1329–1333.
    1. Antoniou A, Pharoah PD, Narod S et al. . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;725:1117–1130.
    1. Kuchenbaecker KB, Hopper JL, Barnes DR et al. . Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;31723:2402–2416.
    1. Williams-Jones B. History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law J. 2002;10:123–146.
    1. U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;1604:271–281.
    1. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;1435:355–361.
    1. Daly MB, Pilarski R, Berry M et al. . NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2017;151:9–20.
    1. Robson ME, Bradbury AR, Arun B et al. . American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;3331:3660–3667.
    1. Kolor K, Chen Z, Grosse SD et al. . BRCA genetic testing and receipt of preventive interventions among women aged 18–64 years with employer-sponsored health insurance in nonmetropolitan and metropolitan areas—United States, 2009–2014. MMWR Surveill Summ. 2017;6615:1–11.
    1. Rosenberg SM, Ruddy KJ, Tamimi RM et al. . BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;26:730–736.
    1. Chen Z, Kolor K, Grosse SD et al. . Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014 Genet Med. 2018;204:428–434.
    1. Kurian AW, Griffith KA, Hamilton AS et al. . Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;3175:531–534.
    1. Kehl KL, Shen C, Litton JK et al. . Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016;1551:165–173.
    1. Wang G, Beattie MS, Ponce NA et al. . Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011;1312:1045–1050.
    1. Kaiser Permanente Washington. Breast Cancer Risk Assessment and Screening Guideline. . Accessed September 18, 2018.
    1. Pocobelli G, Chubak J, Hanson N et al. . Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. Gynecol Oncol. 2012;1262:229–235.
    1. Surveillance Epidemiology and End Results Program. Seattle-Puget Sound Registry. . Accessed September 18, 2018.
    1. Ross TR, Ng D, Brown JS et al. . The HMO research network virtual data warehouse: a public data model to support collaboration. EGEMS (Wash DC). 2014;21:1049.
    1. Lynch J, Berse B. Methods to identify BRCA testing in claims data. Am J Obstet Gynecol. 2016;2151:133–134.
    1. Lynch JA, Berse B, Dotson WD et al. . Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data. Genet Med. 2017;198:890–899.
    1. Taplin SH, Thompson RS, Schnitzer F et al. . Revisions in the risk-based breast cancer screening program at group health cooperative. Cancer. 1990;664:812–818.
    1. Taplin SH, Ichikawa L, Buist DS et al. . Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev. 2004;132:225–234.
    1. Phipps AI, Buist DS. Validation of self-reported history of hysterectomy and oophorectomy among women in an integrated group practice setting. Menopause. 2009;163:576–581.
    1. Guo F, Hirth JM, Lin YL et al. . Use of BRCA mutation test in the U.S., 2004–2014. Am J Prev Med. 2017;526:702–709.
    1. Samimi G, Bernardini MQ, Brody LC et al. . Traceback: a proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach. J Clin Oncol. 2017;3520:2329–2337.
    1. Bellcross CA, Peipins LA, McCarty FA et al. . Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Genet Med. 2015;171:43–50.
    1. McCarthy AM, Bristol M, Fredricks T et al. . Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. 2013;11920:3596–3603.
    1. Childers CP, Childers KK, Maggard-Gibbons M et al. . National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;3534:3800–3806.
    1. Kurian AW, Ford JM. Multigene panel testing in oncology practice: how should we respond? JAMA Oncol. 2015;13:277–278.
    1. Annas GJ, Elias S. 23andMe and the FDA. N Engl J Med. 2014;37011:985–988.
    1. Hughes KS. Genetic testing: what problem are we trying to solve? J Clin Oncol. 2017;3534:3789–3791.
    1. Wood ME, Kadlubek P, Pham TH et al. . Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;328:824–829.
    1. Stoll K, Kubendran S, Cohen SA. The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine. Am J Med Genet C Genet. 2018;1781:24–37.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere